Stock Events

Stock Events

Ironwood Pharmaceuticals 

$4.25
72
+$0.12+2.91% Monday 20:00
+$0.05+1.18%Monday 23:53After hours

Statistics

Day High
4.26
Day Low
4.23
52W High
5.78
52W Low
1.01
Volume
67,004
Avg. Volume
-
Mkt Cap
702.27M
P/E Ratio
7.21
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29OctExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.23
-0.04
0.14
0.33
Expected EPS
0.325
Actual EPS
N/A

Financials

8.11%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
296.15MRevenue
24.02MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IRWD. It's not an investment recommendation.
NVIDIA
21
NVDA
Microsoft
14
MSFT
Alphabet
14
GOOGL
Apple
13
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie, having acquired Allergan, competes in similar therapeutic areas, including gastrointestinal disorders.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca operates in various segments including gastrointestinal, making it a competitor.
Takeda Pharmaceutical
TAK
Mkt Cap57.58B
Takeda Pharmaceutical focuses on gastroenterology among other areas, competing with Ironwood's GI products.
Sanofi
SNY
Mkt Cap107.39B
Sanofi operates in the gastrointestinal space, among others, making it a competitor.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb competes in multiple therapeutic areas including those targeted by Ironwood.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad product portfolio that includes treatments for gastrointestinal diseases.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical segment, competes in the gastrointestinal market.
Merck
MRK
Mkt Cap366B
Merck & Co. competes across various therapeutic areas, including those relevant to Ironwood's focus.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline has a presence in the gastrointestinal therapeutic area, among others.

About

Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
Show more...
CEO
Thomas A. McCourt
Employees
100
Country
United States
ISIN
US46333X1081
WKN
000A0X789

Listings

MU
DE
I76.MU
STU
DE
I76.STU
F
DE
I76.F
XNAS
US
IRWD

0 Comments

Share your thoughts

FAQ

What is Ironwood Pharmaceuticals stock price today?▼
The current price of IRWD is $4.25 USD — it has increased by +2.91% in the past 24 hours. Watch Ironwood Pharmaceuticals stock price performance more closely on the chart.
What is Ironwood Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Ironwood Pharmaceuticals stocks are traded under the ticker IRWD.
Is Ironwood Pharmaceuticals stock price growing?▼
IRWD stock has fallen by -3.19% compared to the previous week, the month change is a +0.47% rise, over the last year Ironwood Pharmaceuticals has showed a +221.97% increase.
What is Ironwood Pharmaceuticals market cap?▼
Today Ironwood Pharmaceuticals has the market capitalization of 702.27M
When is the next Ironwood Pharmaceuticals earnings date?▼
Ironwood Pharmaceuticals is going to release the next earnings report on October 29, 2026.
What were Ironwood Pharmaceuticals earnings last quarter?▼
IRWD earnings for the last quarter are 0.31 USD per share, whereas the estimation was 0.32 USD resulting in a -3.13% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Ironwood Pharmaceuticals revenue for the last year?▼
Ironwood Pharmaceuticals revenue for the last year amounts to 296.15M USD.
What is Ironwood Pharmaceuticals net income for the last year?▼
IRWD net income for the last year is 24.02M USD.
How many employees does Ironwood Pharmaceuticals have?▼
As of September 01, 2026, the company has 100 employees.
In which sector is Ironwood Pharmaceuticals located?▼
Ironwood Pharmaceuticals operates in the Health & Wellness sector.
When did Ironwood Pharmaceuticals complete a stock split?▼
Ironwood Pharmaceuticals has not had any recent stock splits.
Where is Ironwood Pharmaceuticals headquartered?▼
Ironwood Pharmaceuticals is headquartered in BOSTON, United States.